Blood

Vol. 148, Issue 2 Issue 2 2026
17
Articles

Articles in this Issue

Chakraborty R, Brailovsky Y, Hanna M, et al. Prognostic factors and progression biomarkers in AL amyloidosis: mapping current knowledge and critical gaps. <i>Blood</i> . 2026;147(21):2448-2462.

Jul 09, 2026 pp. 262-262 10.1182/blood.2026035071

Platelet-derived TGF-β1 and Treg maintenance in a murine model of ITP

Jasimuddin Ahamed Jul 09, 2026 pp. 258-260 10.1182/blood.2026034039

Abstract Studies suggest that platelet-derived transforming growth factor (TGF)-β1 is critical to immune thrombocytopenia tolerance via regulatory T-cell (Treg) modulation, but the...

MDM4 haploinsufficiency leads to p53-mediated bone marrow failure

Richa Sharma, Senthil Velan Bhoopalan, Robert Meyer et al. Jul 09, 2026 pp. 161-174 10.1182/blood.2024027180

Abstract Bone marrow failure (BMF) syndromes are heterogeneous diseases characterized by impaired hematopoiesis and a risk of evolution to myelodysplastic syndrome (MDS) and leukem...

Platelet TGF-β and Tregs in ITP: going steady or breaking up?

Rick Kapur Jul 09, 2026 pp. 157-159 10.1182/blood.2026034450

FLT3-ITD scaffolds PKCι-STAT1 to drive noncanonical S727 phosphorylation and CD276-driven CD8+ T-cell exhaustion in AML

Yun Wang, Shuzhao Chen, Shutong Liu et al. Jul 09, 2026 pp. 213-228 10.1182/blood.2025032254

Abstract The internal tandem duplications in FMS-like tyrosine kinase 3 (FLT3-ITD) are associated with poor prognosis in acute myeloid leukemia (AML), yet its kinase-independent me...

Fibrin as a thrombin sink: a factor retaining a thrombus in the stillness phase

Alexandra Yakusheva, Catherine Bourdon, Kim Jouffroy et al. Jul 09, 2026 pp. 245-257 10.1182/blood.2025030466

Abstract The process of nonocclusive thrombus formation is well known, but the mechanism keeping the thrombus silent at the end stage remains unclear. The aim of this work was to e...

Soiffer RJ. Graft manipulation and GVHD: what goes around comes around. <i>Blood</i> . 2026;147(11):1137-1138.

Jul 09, 2026 pp. 263-263 10.1182/blood.2026035005

A phase 1/1b study of the BCMA-targeting bispecific T-cell engager pavurutamab for relapsed/refractory multiple myeloma

Hans C. Lee, Wouter J. Plattel, Simon J. Harrison et al. Jul 09, 2026 pp. 199-212 10.1182/blood.2025032044

Abstract The B-cell maturation antigen (BCMA)–targeting bispecific T-cell engager pavurutamab (AMG 701) directs the cytotoxic T-cell response toward multiple myeloma (MM) cells. Th...

An emerging family of bone marrow failure syndromes

Franck Toledo Jul 09, 2026 pp. 149-150 10.1182/blood.2026033530

The rapidly evolving BCMA landscape in multiple myeloma

Niels W. C. J. van de Donk, Sonja Zweegman Jul 09, 2026 pp. 151-152 10.1182/blood.2026034153

Fibrin is a thrombin sink that leads to stillness of thrombi

John W. Weisel, Rustem I. Litvinov Jul 09, 2026 pp. 156-157 10.1182/blood.2026033921

Chasing uncertain significance in <i>PIEZO1</i> variants

Catherine Badens, Hélène Guizouarn Jul 09, 2026 pp. 155-156 10.1182/blood.2026034333

CNS relapse during menin inhibitor therapy

Amy Ku, Aaron D. Viny Jul 09, 2026 pp. 261-261 10.1182/blood.2026034178

Refined classification and phenotype-driven analysis of <i>PIEZO1</i> variants in hereditary red blood cell and iron disorders

Barbara Eleni Rosato, Roberta Marra, Stefania Martone et al. Jul 09, 2026 pp. 229-244 10.1182/blood.2025031632

Abstract Interpreting genetic variants in complex genes such as PIEZO1 remains challenging because of marked allelic heterogeneity, relative tolerance to missense variation, and ov...

Beyond kinase activity: FLT3-ITD scaffolds immune escape

Melissa Zwick, Natalie Köhler Jul 09, 2026 pp. 152-154 10.1182/blood.2026033928

Neutrophils as chameleons of tissue inflammation and host-pathogen interactions

Yanfang Peipei Zhu, Sergio D. Catz, Ben A. Croker Jul 09, 2026 pp. 187-198 10.1182/blood.2025029580

Abstract Neutrophils are acute responders to bacterial and fungal infection; however, their roles in disease extend far beyond their critical roles in countering pathogens. In this...

Unfinished business in chronic lymphocytic leukemia: translational and clinical priorities for a cure

Catherine J. Wu, Federico Caligaris-Cappio, Nicholas Chiorazzi et al. Jul 09, 2026 pp. 175-186 10.1182/blood.2025032393

Abstract Remarkable progress in the understanding of disease pathogenesis and treatment across hematologic malignancies has been achieved in the past 2 decades. Nevertheless, the r...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page